Results 61 to 70 of about 2,554,026 (187)

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Urate-lowering therapy (ULT).

, 2015
1Answers in agreement with the 2012 American College of Rheumatology gout guidelines2participants who reported not to adjust ULT for patients with tophaceous gout based on the SUA level were excluded from other questions that were based on the concept of
Geraldo da Rocha Castelar-Pinheiro (783431), H. Ralph Schumacher Jr. (443559), Ana Beatriz Vargas-Santos (783430), Evandro Silva Freire Coutinho (107557), Naomi Schlesinger (783432), Jasvinder A. Singh (484385)   +5 more
core   +1 more source

Urate-lowering therapy modifies associations between urinary urate and kidney outcome

Renal Failure
Background Serum uric acid is associated with chronic kidney disease (CKD) progression; however, causality remains uncertain. Although renal urate handling, rather than merely hyperuricemia, may dominate kidney outcomes, the prognostic value of urinary ...
Tomoaki Takata, Yukari Mae, Shotaro Hoi, Naoyuki Otani, Takaaki Sugihara, Ichiro Hisatome, Hajime Isomoto   +6 more
doaj   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras Serrano, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Comparative Effects of Angiotensin Receptor Blockers on Blood Pressure and Serum Urate in Patients With Hypertension and Hyperuricaemia: A Systematic Review and Network Meta‐Analysis

Medicine Bulletin, EarlyView.
Allisartan ranked best for serum urate reduction and showed favourable blood pressure control, whereas losartan also performed well overall. These rankings may inform ARB selection but should be interpreted cautiously because of inconsistency, heterogeneity and sparse direct evidence.
Xuanyao Li, Xinyi Wang, Xiaolei Ren, Yalin Wang, Hua Shao, Xueli Zhang   +5 more
wiley   +1 more source

Farnesoid X receptor prevents hyperuricemia via activating ATP‐binding cassette subfamily G member 2

Rheumatology &Autoimmunity, EarlyView.
Farnesoid X receptor (FXR) activation reduces serum uric acid levels by upregulating the intestinal urate transporter ATP‐binding cassette subfamily G member 2 (ABCG2). These findings uncover a novel metabolic pathway for urate excretion and suggest that FXR agonists (e.g., obeticholic acid), represent a promising therapeutic strategy for the treatment
Rui Li, Guo Tang, Ye Yu, Guang‐Liang Chen, Liangjing Lu, Juan Wang   +5 more
wiley   +1 more source

Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial [PDF]

The American Journal of Medicine, 2019
The purpose of this study was to test a pharmacist-led intervention to improve gout treatment adherence and outcomes.We conducted a site-randomized trial (n=1463 patients) comparing a 1-year, pharmacist-led intervention to usual care in patients with gout initiating allopurinol.
Ted R. Mikuls, T. Craig Cheetham, Gerald D. Levy, Nazia Rashid, Artak Kerimian, Kimberly J. Low, Brian W. Coburn, David T. Redden, Kenneth G. Saag, P. Jeffrey Foster, Lang Chen, Jeffrey R. Curtis   +11 more
openaire   +2 more sources

Inflammatory Bowel Disease Is Associated With an Increased Risk of End‐Stage Renal Disease: A Population‐Based Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a retrospective population‐based cohort study using the University of Manitoba IBD Epidemiology Database, persons with IBD have an increased risk of ESRD by nearly 50%, with CD showing greater risk than UC. Bowel surgery, allopurinol use and oral steroid therapy are important predictors, emphasising the necessity of careful renal monitoring in IBD ...
Onuma Sattayalertyanyong, Zoann Nugent, Bryce Barr, Keevin N. Bernstein, Charles N. Bernstein   +4 more
wiley   +1 more source

Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice

Frontiers in Medicine, 2020
Limitations in efficacy and/or tolerance of currently available urate-lowering therapies (ULTs), such as oral xanthine oxidase inhibitors, uricosurics, and intravenous uricase agents contribute to the development of refractory gout.
Kateryna Pierzynowska, Kateryna Pierzynowska, Kateryna Pierzynowska, Aditi Deshpande, Nadiia Mosiichuk, Robert Terkeltaub, Paulina Szczurek, Eduardo Salido, Stefan Pierzynowski, Stefan Pierzynowski, Stefan Pierzynowski, Danica Grujic   +11 more
doaj   +1 more source

Maternal nutrition as a key determinant of placental and developing blood–brain barrier xenobiotic protective functions

The Journal of Physiology, EarlyView.
Abstract figure legend Suboptimal maternal nutrition alters placental and developing blood–brain barrier (BBB) protective function and is associated with increased fetal brain vulnerability. In the placenta, nutritional adversity may reduce the exchange surface area and promote meta‐inflammation, compromising barrier efficiency in a model‐ and context ...
Kristin L. Connor, Nycolle I. S. Souza, Bruno G. Anjos, Stephen G. Matthews, Enrrico Bloise   +4 more
wiley   +1 more source